NCT06916065View on ClinicalTrials.gov

A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

PHASE1RecruitingINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

April 9, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
OverweightObesity
Interventions
DRUG

Eloralintide and Tirzepatide

Administered SC

DRUG

Eloralintide

Administered SC

Trial Locations (3)

32117

RECRUITING

Fortrea Clinical Research Unit, Daytona Beach

75247

RECRUITING

Fortrea Clinical Research Unit, Dallas

92801

RECRUITING

Anaheim Clinical Trials, LLC, Anaheim

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY